ATE477274T1 - Gegen clostridium difficile gerichtete antikörper - Google Patents

Gegen clostridium difficile gerichtete antikörper

Info

Publication number
ATE477274T1
ATE477274T1 AT04727315T AT04727315T ATE477274T1 AT E477274 T1 ATE477274 T1 AT E477274T1 AT 04727315 T AT04727315 T AT 04727315T AT 04727315 T AT04727315 T AT 04727315T AT E477274 T1 ATE477274 T1 AT E477274T1
Authority
AT
Austria
Prior art keywords
clostridium difficile
directed against
antibodies directed
against clostridium
seq
Prior art date
Application number
AT04727315T
Other languages
English (en)
Inventor
James Burnie
Ruth Matthews
Original Assignee
Neutec Pharma Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neutec Pharma Plc filed Critical Neutec Pharma Plc
Application granted granted Critical
Publication of ATE477274T1 publication Critical patent/ATE477274T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1282—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Clostridium (G)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/563—Immunoassay; Biospecific binding assay; Materials therefor involving antibody fragments
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/33—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Clostridium (G)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation
AT04727315T 2003-04-17 2004-04-14 Gegen clostridium difficile gerichtete antikörper ATE477274T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0309126.1A GB0309126D0 (en) 2003-04-17 2003-04-17 Clostridium difficile focussed antibodies
PCT/GB2004/001619 WO2004094474A1 (en) 2003-04-17 2004-04-14 Clostridium difficile focussed antibodies

Publications (1)

Publication Number Publication Date
ATE477274T1 true ATE477274T1 (de) 2010-08-15

Family

ID=9957095

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04727315T ATE477274T1 (de) 2003-04-17 2004-04-14 Gegen clostridium difficile gerichtete antikörper

Country Status (8)

Country Link
US (1) US20070071763A1 (de)
EP (2) EP2261253A3 (de)
JP (1) JP2007527370A (de)
AT (1) ATE477274T1 (de)
CA (1) CA2522086A1 (de)
DE (1) DE602004028592D1 (de)
GB (1) GB0309126D0 (de)
WO (1) WO2004094474A1 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0130267D0 (en) * 2001-12-19 2002-02-06 Neutec Pharma Plc Focussed antibody technology
GB0414886D0 (en) 2004-07-02 2004-08-04 Neutec Pharma Plc Treatment of bacterial infections
EP1833510A4 (de) * 2004-12-27 2010-02-10 Progenics Pharmaceuticals Neva Oral verabreichbare und anti-toxin-antikörper und herstellungs- und anwendungsverfahren dafür
EP2088432A1 (de) * 2008-02-11 2009-08-12 MorphoSys AG Verfahren zur Identifikation eines Antikörpers oder eines Targets
WO2010094970A1 (en) 2009-02-20 2010-08-26 Health Protection Agency Antibodies to clostridium difficile toxins
US8685896B2 (en) 2009-05-29 2014-04-01 Morphosys Ag Collection and methods for its use
GB0921288D0 (en) 2009-12-04 2010-01-20 Health Prot Agency Therapies for preventing or suppressing clostridium difficile infection
EP2640742B1 (de) 2010-11-19 2018-08-15 MorphoSys AG Eine sammlung von antikörpersequenzen und deren verwendungen
CA2845884A1 (en) 2011-08-22 2013-02-28 Cangene Corporation Clostridium difficile antibodies
CA2856085C (en) 2011-11-18 2020-06-30 National Research Council Of Canada Clostridium difficile lipoteichoic acid and uses thereof
RU2628305C2 (ru) 2012-03-02 2017-08-15 Регенерон Фармасьютиказ, Инк. Человеческие антитела к токсинам clostridium difficile
EP2921502A4 (de) * 2012-10-19 2016-09-28 Evec Inc Gegen toxin aus clostridium difficile oder antigenbindendem fragment spezifischer menschlicher antikörper
CA2892973A1 (en) * 2012-11-28 2014-06-05 Cnj Holdings, Inc. Antibodies against clostridium difficile
SG11201503719WA (en) * 2012-11-29 2015-06-29 Bayer Healthcare Llc MONOCLONAL ANTIBODIES AGAISNT ACTIVATED PROTEIN C (aPC)
RU2020122822A (ru) 2017-12-12 2022-01-13 Макродженикс, Инк. Биспецифичные связывающие cd16 молекулы и их применение при лечении заболеваний
WO2022061292A2 (en) * 2020-09-21 2022-03-24 The Board Of Regents Of The University Of Texas System Therapeutic agents and uses thereof

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
DE3430339C1 (de) 1984-08-17 1986-02-20 Nixdorf Computer Ag, 4790 Paderborn Empfangsschaltung fuer ein bipolares Eingangssignal
EP0173494A3 (de) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimäre Rezeptoren durch Verbindung und Expression von DNS
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
GB8720833D0 (en) 1987-09-04 1987-10-14 Celltech Ltd Recombinant dna product
EP0393045B1 (de) 1987-09-09 1995-03-29 Celltech Therapeutics Limited Fv Antikörperfragment-Herstellung
US6291158B1 (en) * 1989-05-16 2001-09-18 Scripps Research Institute Method for tapping the immunological repertoire
AU702405B2 (en) 1994-09-06 1999-02-18 Immucell Corporation Therapeutic treatment of clostridium difficile associated diseases
GB9621295D0 (en) * 1995-12-07 1996-11-27 Cambridge Antibody Tech Specific binding members,materials and methods
DE19739685A1 (de) * 1997-09-10 1999-03-11 Eichel Streiber Christoph Von Monoklonale Antikörper zur Therapie und Prophylaxe von Erkrankungen durch Clostridium difficile
EP2305303A3 (de) 1997-10-20 2013-11-13 Sanofi Pasteur Biologics Co. Immunisierung gegen Clostridium difficile-Erkrankung
RU2225118C2 (ru) * 1998-04-01 2004-03-10 Даниско А/С Способ изготовления выпечного продукта (варианты), выпечной продукт (варианты), применение немальтогенной экзоамилазы, улучшающая композиция для теста и тесто для выпечного продукта
AU5285899A (en) * 1998-07-21 2000-02-14 Connex Gesellschaft Zur Optimierung Von Forschung Und Entwicklung Mbh Anti hepatitis c virus antibody and uses thereof
US6624295B1 (en) * 1998-08-28 2003-09-23 Genentech, Inc. Human anti-factor IX/IXa antibodies
GB0008305D0 (en) 2000-04-06 2000-05-24 Neutec Pharma Plc Treatment of fungal infections
US20030054009A1 (en) 2001-02-09 2003-03-20 Windle Henry J. Clostridium difficile vaccine
GB0130267D0 (en) * 2001-12-19 2002-02-06 Neutec Pharma Plc Focussed antibody technology

Also Published As

Publication number Publication date
US20070071763A1 (en) 2007-03-29
EP1613655A1 (de) 2006-01-11
WO2004094474A1 (en) 2004-11-04
CA2522086A1 (en) 2004-11-04
JP2007527370A (ja) 2007-09-27
EP2261253A2 (de) 2010-12-15
DE602004028592D1 (de) 2010-09-23
EP1613655B1 (de) 2010-08-11
EP2261253A3 (de) 2011-06-01
GB0309126D0 (en) 2003-05-28

Similar Documents

Publication Publication Date Title
ATE477274T1 (de) Gegen clostridium difficile gerichtete antikörper
NZ588457A (en) Humanized anti-factor d antibodies and uses thereof
IL267186B (en) Regulatory t-cell epitopes, their preparations and uses
DE60322188D1 (de) Zytokin (zcytor17-ligand)
EA200401198A1 (ru) АНТИТЕЛА ПРОТИВ αvβ6
RS54468B1 (en) MONOCLONAL ANTIBODIES AGAINST CLAUDINE-18 FOR THE CANCER TREATMENT
DE60131456D1 (de) Transchromosomale transgen-nagetiere zur herstellung von humänen antikörpern
NZ604090A (en) Human anti-b7rp1 neutralizing antibodies
RS52439B (en) HUMAN ANTIBODIES TO THE HUMAN DELTA SIMILAR LIGAND 4
RS54046B1 (en) ANTI-MIOSTATIN ANTITELA
ATE554107T1 (de) Als therapeutika geeignete monovalente antikörperfragmente
RS52769B (sr) Kompozicije i postupci za povećanje mineralizacije kostiju
NZ623319A (en) Human antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof
NZ626665A (en) Anti-n3pglu amyloid beta peptide antibodies and uses thereof
EE200700052A (et) Antikeha he v?i mitme apo-lipoproteiin B fragmendi vastu
NZ590890A (en) Neutralizing anti-influenza a virus antibodies and uses thereof
RS52782B (en) HIGH AFINITY HUMAN ANTIBODIES FOR THE HUMAN IL-4 RECEPTOR
NZ717847A (en) Human antigen binding proteins that bind beta-klotho, fgf receptors and complexes thereof
DE602006010072D1 (de) Il-1 bindende antikörper und fragmente davon
NZ598063A (en) Gram-positive bacteria specific binding compounds
NZ585622A (en) Hepatitis c virus antibodies
RS54066B1 (en) COMPLETELY HUMAN ANTI-VAP-1 MONOCLONAL ANTIBODIES
WO2007117577A3 (en) High affinity human antibodies to human il-18 receptor
EE200500012A (et) Peptiid-pähine passiivne immunoteraapia ateroskleroosi raviks
RS53160B (en) HUMANIZED BETA AMILOID ANTIBODY

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties